{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:01:21Z","timestamp":1791820881805,"version":"4.3.4"},"reference-count":24,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2018.8708","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T12:02:10Z","timestamp":1526299330000},"source":"Crossref","is-referenced-by-count":2,"title":["Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non\u2011small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report"],"prefix":"10.3892","author":[{"given":"Teppei","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi 470\u20111192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi 470\u20111192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Hattori","sequence":"additional","affiliation":[{"name":"Department of Radiology, Fujita Health University, Toyoake, Aichi 470\u20111192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Fujita Health University, Toyoake, Aichi 470\u20111192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi 470\u20111192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"key20200714082825_b1-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200714082825_b2-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b3-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200714082825_b4-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b5-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutations-positive non-small cell lung cancer (EURTAC) a multicenter, open-label, randomized phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b6-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200714082825_b7-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b8-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20200714082825_b9-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"key20200714082825_b10-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdv063","article-title":"Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005\/TCOG0902","volume":"26","author":"Sugawara","year":"2015","journal-title":"Ann Oncol"},{"key":"key20200714082825_b11-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/JTO.0000000000000434","article-title":"Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The okayama lung cancer study group trial 1001","volume":"10","author":"Ichihara","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key20200714082825_b12-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b13-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"24","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20200714082825_b14-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20200714082825_b15-ol-0-0-8708","journal-title":"US Food and Drug Administration, Center for Drug Evaluation and Research: AVASTIN (bevacizumab) solution for intravenous infusion [product label]"},{"key":"key20200714082825_b16-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1097\/JTO.0b013e3181b27799","article-title":"International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions: The IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"4","author":"Valli\u00e8res","year":"2009","journal-title":"J Thorac Oncol"},{"key":"key20200714082825_b17-ol-0-0-8708","author":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 Published: May28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services","journal-title":"National Institute of Health National Cancer Institute"},{"key":"key20200714082825_b18-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20200714082825_b19-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A review on bevacizumab and surgical wound healing: An important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"key20200714082825_b20-ol-0-0-8708","journal-title":"US Food and Drug Administration, Center for Drug Evaluation and Research: Tarceva (erlotinib) tablets for oral use [product label]"},{"key":"key20200714082825_b21-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cllc.2014.07.005","article-title":"Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer","volume":"16","author":"Chu","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"key20200714082825_b22-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","article-title":"Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer","volume":"34","author":"van Leeuwen","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20200714082825_b23-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1006\/gyno.1997.4842","article-title":"A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer","volume":"67","author":"Seewaldt","year":"1997","journal-title":"Gynecol Oncol"},{"key":"key20200714082825_b24-ol-0-0-8708","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T08:48:10Z","timestamp":1594716490000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2018.8708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":24,"URL":"https:\/\/doi.org\/10.3892\/ol.2018.8708","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,14]]}}}